Clinical trial
Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant…
NCT00231335 · Emory University, Other · Completed
Key facts
| NCT number | NCT00231335 |
|---|---|
| Title | Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia |
| Official title | The Efficacy and Safety of Escitalopram Augmentation of Risperidone and Olanzapine in Treatment Resistant Schizophrenia: a Double Blind Placebo Controlled Pilot Study |
| Lead sponsor | Emory University, Other |
| Collaborators | Forest Laboratories Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | escitalopram |
| Enrollment | 30 |
| Start date | Mar 1, 2006 |
| Completion | Jul 1, 2007 |
| First posted | Oct 4, 2005 |
| Last update posted | Dec 7, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: